文献速递免疫规划

一项III期开放标签随机多中心研究:评估两种不同减抗原百白破-灭活脊髓灰质炎疫苗加强剂与麻腮风疫苗联合接种在3至4岁健康儿童中的免疫原性和安全性

A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
PubMed 文献 · Vaccine · 2018-03-22

该III期开放标签随机多中心研究于2011年4月至2012年4月在英国开展,将387名3至4岁儿童按2:1随机分配接种dTap-IPVB或dTap-IPVR并与MMRV联合接种。结果显示dTap-IPVB对dTap-IPVR的非劣效性得到证实,两种疫苗均具有临床可接受的安全性和反应原性。

要点

  • 387名儿童随机分组,385名接种:dTap-IPVB组255名,dTap-IPVR组130名。
  • 接种前≥76.8%儿童抗白喉、≥65.5%抗破伤风滴度高于保护阈值。
  • 两种疫苗免疫原性良好,99.2%至100%儿童达到预设血清保护/血清阳性阈值。

核心结论

  • dTap-IPVB对dTap-IPVR的非劣效性得到证实。
  • 两种疫苗与MMRV联合接种于3至4岁儿童时均具有临床可接受的安全性和反应原性。

研究设计与样本

  • III期开放标签随机多中心研究,2011年4月至2012年4月在英国开展。
  • 387名儿童随机分组,385名接种:dTap-IPVB组255名,dTap-IPVR组130名,随机比2:1。
  • 接种前及接种后一个月采集血样评估免疫原性。
  • 白喉、破伤风、脊髓灰质炎抗原的免疫应答在研究疫苗间进行比较性分析。
  • 无公认百日咳保护相关物时,dTap-IPVB对百日咳的免疫原性与历史百日咳效力数据进行比较性分析。

主要发现

  • 接种前≥76.8%儿童抗白喉滴度、≥65.5%抗破伤风滴度高于保护阈值。
  • 接种前百日咳血清阳性率范围为18.1%至70.6%。
  • 两种疫苗均具免疫原性,99.2%至100%儿童达到预设血清保护/血清阳性阈值。
  • dTap-IPVB组报告1例严重不良事件,研究者认为与 study vaccination 无因果关系。

关键数值与推荐

  • dTap-IPVB对dTap-IPVR非劣效性得到证实。
  • 两种疫苗与MMRV联合接种于3至4岁儿童时安全性和反应原性临床可接受。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To evaluate the immunogenicity and safety of a reduced antigen diphtheria-tetanus-acellular pertussis-inactivated poliovirus (dTap-IPVB) vaccine (Boostrix-IPV, GSK) as a pre-school booster in 3-4 year old children as compared to dTap-IPVR (Repevax, Sanofi Pasteur), when co-administered with mumps-measles-rubella vaccine (MMRV). METHODS: This phase III, open label, randomised study was conducted in the UK between April 2011 and April 2012. Children due their pre-school dTap-IPV booster vaccination were randomised 2:1 to receive one of two different dTap-IPV vaccines (dTap-IPVB or dTap-IPVR) with blood sample for immunogenicity assessment just prior and one month after vaccination. Immune responses to diphtheria, tetanus and polio antigens were compared between the study vaccines (inferential comparison). In the absence of an accepted pertussis correlate of protection, the immunogenicity of dTap-IPVB vaccine against pertussis was compared with historical pertussis efficacy data (inferential comparison). Safety and reactogenicity of both study vaccines were evaluated. RESULTS: 387 children were randomised and 385 vaccinated: 255 in the dTap-IPVB group and 130 in the dTap-IPVR group. Prior to vaccination, ≥76.8% of children had anti-diphtheria and ≥65.5% had anti-tetanus titres above the protection threshold; for pertussis, the pre-vaccination seropositivity rate ranged between 18.1 and 70.6%. Both vaccines were immunogenic with 99.2-100% of children achieving titres above the pre-specified seroprotection/seropositivity thresholds. One serious adverse event not considered as causally related to the study vaccination by the study investigator was reported in the dTap-IPVB group. CONCLUSION: Non-inferiority of dTap-IPVB to dTap-IPVR was demonstrated. Both vaccines had a clinically acceptable safety and reactogenicity profile when co-administered with MMRV to children 3-4 years old. TRIAL REGISTRATION: NCT01245049 (ClinicalTrials.gov).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Marlow R, Kuriyakose S, Mesaros N, et al. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK. Vaccine. 2018. PMID: 29576304. doi:10.1016/j.vaccine.2018.03.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。